Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Signal Transducers and Activators of Transcription 1 (STAT1), STAT2, and T Cells Mediate Interferon-Dependent Protection Against Neurobrucellosis.

The Journal of infectious diseases·2025

Same author

Metabolomic analysis of murine tissues infected with Brucella melitensis.

PloS one·2025

Same author

Metabolomic Analysis of Murine Tissues Infected with <i>Brucella melitensis</i>.

bioRxiv : the preprint server for biology·2024

Same author

Vaccine-Elicited Antibodies Restrict Glucose Availability to Control Brucella Infection.

The Journal of infectious diseases·2024

Same author

Contrasting roles for IgM and B-cell MHCII expression in <i>Brucella abortus</i> S19 vaccine-mediated efficacy against <i>B. melitensis</i> infection.

mSphere·2024

Same author

Interactions between B cells and T follicular regulatory cells enhance susceptibility to Brucella infection independent of the anti-Brucella humoral response.

PLoS pathogens·2023

Search research articles

Related Experiment Video

Updated: May 8, 2026

Intratracheal Inoculation of Fischer 344 Rats with Francisella tularensis

Intratracheal Inoculation of Fischer 344 Rats with Francisella tularensis

Published on: September 30, 2017

Immunotherapy for tularemia.

Jerod A Skyberg¹

¹Department of Veterinary Pathobiology and Laboratory for Infectious Disease Research; University of Missouri; Columbia, MO USA.

|August 21, 2013

Summary

Francisella tularensis causes lethal tularemia, and no vaccines exist. This review explores immunotherapy and host immunity augmentation as crucial countermeasures against this bioterrorism threat.

Area of Science:

Microbiology
Immunology
Infectious Diseases

Background:

Francisella tularensis is a highly infectious gram-negative bacterium causing severe, often fatal, tularemia, particularly via respiratory infection.
No licensed vaccines are available for human tularemia prevention.
The bacterium's potential for weaponization, including antibiotic resistance, necessitates alternative countermeasures.

Purpose of the Study:

To review recent advances in immunotherapy for tularemia.
To discuss challenges in developing effective immunotherapy strategies.
To highlight the importance of augmenting host immunity against F. tularensis.

Main Methods:

Literature review of studies on immunotherapy and host immunity augmentation for tularemia.

Keywords:

Francisella biodefense immunity immunotherapy pathogen tularemia

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

Related Experiment Videos

Last Updated: May 8, 2026

Intratracheal Inoculation of Fischer 344 Rats with Francisella tularensis

Intratracheal Inoculation of Fischer 344 Rats with Francisella tularensis

Published on: September 30, 2017

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

Analysis of current research on F. tularensis pathogenesis and treatment limitations.

Synthesis of findings on experimental countermeasures.

Main Results:

Immunotherapy, including humoral approaches, shows promise in preclinical models.
Augmenting host immunity is a viable strategy to combat F. tularensis infection.
Significant challenges remain in translating research findings into clinical applications.

Conclusions:

Immunotherapy represents a critical area of research for tularemia countermeasures.
Further development is needed to overcome challenges in efficacy and delivery.
Addressing the threat of F. tularensis requires a multi-pronged approach including immunotherapy.